Health Canada approved the first generic semaglutide on April 28, 2026. The pricing story is the easy part. The harder conversation is what role your benefits plan should play in giving employees access to it.
If you offer a group drug plan in Canada, this question is about to land on your desk or probably already has.
On Tuesday, April 28, 2026, Health Canada issued a Notice of Compliance to Dr. Reddy’s Laboratories for the first generic semaglutide injection. It’s the first generic Ozempic approved anywhere in the G7.
Quick reminder on Brand name vs Generic:
So, now the question from clients is …. Should we be covering this for weight management now that prices are coming down? Let’s dive in…
A quick note on what this post is and isn’t. We’re a benefits brokerage, not clinicians. This Blog is a collection of resources, from approved indications, research from Health Canada, peer-reviewed journals, and industry reports; it is not our interpretation. What we do is help employers think through plan design and coverage decisions for your benefits plan.
What Health Canada actually approved on April 28th
Health Canada authorized a generic semaglutide injection from Dr. Reddy’s Laboratories, an India-based generic manufacturer. The approval is for the once-weekly treatment of adults with type 2 diabetes.
Quick reminder on indication vs off indication:
A few details to consider here:
- The approval is for the diabetes indication only. Wegovy, the higher-dose semaglutide approved for weight loss, is a separate product. Its generic isn’t here yet, and none have been submitted to Health Canada for review.
- Approval doesn’t equal availability. Dr. Reddy’s has launch preparations underway, but generics typically take months to reach pharmacy shelves at scale. Industry expectation is late 2026.
- Health Canada is reviewing eight more generic submissions right now. Real price competition kicks in once a second product enters the market.
What semaglutide is approved to do
- Manage blood sugar in adults with type 2 diabetes. This is Ozempic’s original indication and the basis for the April 28 generic approval.
- At a higher dose (Wegovy), support chronic weight management in adults with obesity or overweight with weight-related conditions. The SELECT trial demonstrated a 20% reduction in major cardiovascular events in high-risk patients on Wegovy. Average weight loss in clinical trials runs 10–15% of body weight.
- Reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The FDA expanded Ozempic’s indication for this in January 2025 based on the FLOW trial, which showed a 24% reduction in the primary kidney composite endpoint.
- Treat noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis. Wegovy received FDA accelerated approval for this in August 2025.
- A related GLP-1 class drug, tirzepatide, was approved by the FDA in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, the first prescription medication ever approved for sleep apnea.
These are well-documented, regulator-approved uses. Whether and how Health Canada has matched each U.S. approval, and how your carrier’s formulary handles each indication, is worth confirming directly with us, or your benefits administrator.
What employees are also using it for
Beyond approved indications, semaglutide and other GLP-1s are increasingly being prescribed off-label, and a growing body of research is exploring further uses. Some of this is showing up in claims data already; some of it is years away from clinical practice.
- Off-label weight management. Semaglutide (the Ozempic dose) being prescribed for weight loss in patients who don’t have type 2 diabetes or who don’t meet the obesity threshold for Wegovy. This is the most common off-label use today.
- Polycystic ovary syndrome (PCOS). Liraglutide (an earlier GLP-1) has shown improvements in ovarian dysfunction in women with PCOS who also have overweight. Off-label semaglutide prescribing for PCOS is increasingly common.
- Pre-diabetics and metabolic syndrome. Patients with elevated A1C or insulin resistance, but not yet a type 2 diagnosis, are being prescribed GLP-1s for prevention.
- Active research areas. Clinical trials are studying GLP-1s for alcohol and other substance use disorders, Alzheimer’s and Parkinson’s disease, and depression. A large observational study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 use was associated with a 14% lower risk of developing alcohol, cannabis, cocaine, nicotine, and opioid use disorders. Important context: that’s an observational association in a specific population, not causal evidence, and none of these uses is currently approved.
The takeaway isn’t that GLP-1 coverage should anticipate every emerging use. It’s that the population of employees who might benefit is broader than “people trying to lose weight.” Some are managing diabetes. Some have kidney or cardiovascular disease. Some are dealing with PCOS or sleep apnea. That breadth matters for plan design, and it matters for how employees experience the coverage decision.
Two facts worth flagging for plan design
For weight management, this is typically a long-term medication. When patients stop, a 2022 clinical trial showed they regained about 12% of body weight within a year, after losing an average of 17% on the drug. JAMA Network Open found the majority of GLP-1 weight-loss patients quit within two years, and most see weight return when they do. (Diabetes prescribing is also long-term, but that’s standard for diabetes pharmacotherapy.) For employers, the practical implication is that adding weight-management coverage isn’t a short-term cost; it’s an ongoing prescription category to plan around.
Mental health considerations are documented. The European Medicines Agency reviewed safety data on GLP-1s and reported no causal connection with depression or suicidal behaviour. The FDA has, however, received nearly 500 reports of mood-related adverse events in connection with semaglutide medications. For patients with pre-existing mental health conditions, prescribing information consistently recommends a physician conversation before starting GLP-1 therapy.
Why this question is about to land on your desk
Two things are converging.
First, more employees are already taking it. According to a recent TELUS report, weight-management drug spend grew 61% in 2025 on top of 104% the year before. The category jumped from 29th to 11th in three years. Whether your plan covers it for weight management or not, your employees are using GLP-1 medications. They’re paying privately. They’re hearing about it everywhere. And they’re going to ask you whether the plan can help.
Second, the price floor is shifting. Until now, weight-management coverage was effectively unaffordable for almost any small or mid-sized employer to add at the formulary level. The math just didn’t work. With generic pricing landing at roughly a third of brand cost, the conversation moves from “we can’t” to “do we?”.
Where your benefits plan actually fits in
Here’s the part of the conversation we keep coming back to with clients.
It is not your job, as an employer, to evaluate whether semaglutide is good or bad medicine. That’s between an employee, their physician, and their pharmacist. Your benefits plan exists to support people who are making healthcare decisions. Full stop.
The people most affected by this coverage decision are the employees/spouses who are already managing type 2 diabetes, obesity, kidney disease, PCOS, sleep apnea, cardiovascular risk.
What your plan does, is decide which categories of medication are covered, at what level, with what guardrails. Adding a category to your formulary isn’t an endorsement of every prescription written within it. It’s a decision about whether financial access should be part of the support your plan provides and how that access is structured.
The question isn’t “is this drug right for our people.” The question is closer to:
- Is this a category our team is asking for, and would coverage materially change their access to it?
- Can our plan absorb the cost? Reviewing that GLP-1s are typically a long-term medication, not a one-time treatment.
- How does this fit alongside the rest of our wellness, mental health, and chronic disease support? Is coverage alone enough, or does it need to come with education and adjacent supports?
Those are employer questions. They have employer answers. None of them require you to play pharmacist.
On the cost side, the TELUS Health 2026 Drug Trends Report estimates generic semaglutide will arrive at roughly 35% of brand list price, dropping annual treatment costs from a current range of $1,500–$6,100 to roughly $500–$2,100 per patient, depending on dosage. For employers already covering Ozempic for diabetes, that’s meaningful relief on one of the larger spend categories. For employers being asked about adding weight-management coverage, that’s the math that’s about to make the question feel viable when it didn’t before.
Five questions to ask before adding GLP-1 coverage to your formulary
- What’s our current GLP-1 utilization, and what’s it trending toward? Even if your plan doesn’t cover semaglutide for weight management, look at what’s being claimed for diabetes. If that line is climbing, your renewal trajectory is already changing.
- How is our carrier going to handle generic substitution? Manulife, Sun Life, Canada Life, Desjardins, GreenShield, Equitable Life — each will adjust on its own timeline. Mandatory generic substitution flows costs through faster than preferred-but-optional policies. Ask specifically.
- Are we communicating this well to our team? Coverage decisions land differently when employees understand them. If you add GLP-1 coverage, share what’s covered, what’s required to access it, and where to find good information about benefits and risks.
- What does our claims data say a year from now? This is a category that’s still maturing. The TELUS report flagged that patients are already migrating from Ozempic to Mounjaro (tirzepatide), which is more effective. Whatever you decide this year deserves a real review next year. The data will keep telling you something.
The bigger picture
If you’ve been bracing for another drug plan increase, generic Ozempic offers some genuine breathing room, particularly if you already cover semaglutide for diabetes. The same TELUS report that highlighted the weight-management surge also flagged ultra-high-cost specialty drugs as the real long-term pressure on private plans. Specialty drugs accounted for 33.9% of total eligible drug spend in 2025, used by just 2.1% of claimants. Yep, two percent of plan members are driving a third of spend.
A price drop in the 60–70% range on one molecule is good news. It doesn’t fix the underlying pressure, but it gives you breathing room and a real decision to make about how to use it.
Add to that, the federal Pharmacare Act for diabetes drugs, which took effect October 2024 — Manitoba and PEI rolled out programs in 2025, BC came online in March 2026. As more provinces participate, private plans pay less for diabetes drugs because public coverage steps in first. That’s another piece of cost relief running parallel to the generic story.
The combination matters. Drug plan savings can help you redeploy funds into broader access, better mental health support, more meaningful coverage on the categories your team actually uses.
Generic Ozempic and group benefits: frequently asked questions
Is generic Ozempic available at my pharmacy now?
Approval came on April 28, 2026, but actual pharmacy availability is expected later in 2026. Approval and availability are two different things in Canadian pharmacy supply. Ask your pharmacist or your benefits carrier when generic semaglutide will actually be substituted on your plan.
Should we add weight-management coverage to our plan now that prices are dropping?
Adding it now means paying brand-name pricing on a category that’s about to see significant cost change. Let pricing settle, see what your carrier publishes, and make the call on real numbers.
Does this approval cover Wegovy or weight-loss prescriptions?
No. The April 28 approval is for semaglutide indicated for type 2 diabetes. Wegovy is a separate, higher-dose product approved for weight management, and no generic version has been submitted to Health Canada for review yet. Wegovy generics will follow eventually, but they aren’t part of this update.
Is the employer’s role to evaluate whether the drug is good or bad?
No. That’s a clinical decision between an employee and their physician. The employer’s role is to decide what role the benefits plan plays in providing access, including which categories of medication are covered, at what level, and with what guardrails. Education is part of that role. Pharmaceutical evaluation isn’t.
My employee is on Ozempic for weight loss and pays out of pocket. Does this approval help them?
Yes, eventually. Lower generic prices will reduce out-of-pocket costs for employees buying semaglutide privately, even if your plan doesn’t cover it for weight management. That’s a quality-of-life win for those employees regardless of plan design.
Should I expect my drug plan renewal to come down because of this?
Probably not in your next renewal cycle. Generic launch is expected late 2026, and carriers calculate renewals based on the previous 12 months of claims. The cost relief would show up earliest in 2027 benefit renewals. Unless you are self-funded (ASO).
If you’d like to walk through what this approval means specifically for your plan and your formulary including what your team is already claiming, what the cost picture looks like under different coverage scenarios, and how to communicate any change well, we are happy to help..
One Response